September 13th 2024
Grzegorz S. Nowakowski, MD, discusses unmet needs that remain to be addressed in patients with relapsed/refractory follicular lymphoma.
September 6th 2024
Grzegorz S. Nowakowski, MD, discusses the treatment landscape for DLBCL and the need for novel therapeutic approaches in the second-line setting.
September 4th 2024
Grzegorz S. Nowakowski, MD, discusses results from the EPCORE NHL-1 trial of third-line epcoritamab in relapsed/refractory follicular lymphoma.
July 17th 2024
Grzegorz S. Nowakowski, MD, discusses the significance of the FDA approval of epcoritamab in relapsed/refractory follicular lymphoma.
February 20th 2024
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
February 13th 2024
A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.
Experts on mantle cell lymphoma discuss third-line treatment options available for patients.
February 6th 2024
Experts on mantle cell lymphoma discuss second-line treatment options available for patients.
A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.
January 30th 2024
Experts on mantle cell lymphoma discuss first-line treatment options available for patients.
Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.
January 23rd 2024
Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.
Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.
January 16th 2024
A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.
Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.
January 10th 2024
Grzegorz S. Nowakowski, MD, discusses data from the phase 1/2 TakeAim Lymphoma trial of emavusertib plus ibrutinib in patients with hematologic malignancies.
Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.
Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.
January 2nd 2024
Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.
Experts on follicular lymphoma discuss second-line treatment options available for patients.